03:57 PM EDT, 07/30/2024 (MT Newswires) -- Tempus AI ( TEM ) said Tuesday it has expanded its data and sequencing collaboration with Remix Therapeutics.

The expanded alliance includes an evaluation of groups, including adenoid cystic carcinoma and acute myeloid leukemia, using Tempus' data analytics platform Lens, as well as providing next-generation sequencing support for Remix's phase 1 trial of messenger RNA degrader REM-422, Tempus said.

Financial details weren't disclosed.

Shares of Tempus were up 4.4% in recent trading.

Price: 45.82, Change: +1.95, Percent Change: +4.43